Injectable division
CagriSema
AClass-leading
Novo Nordisk · certified
vs
Injectable division
Survodutide
LaggingC
Boehringer Ingelheim · certified
17% · leads
Efficacy
8%
Mild (+2.3) · gentler
Tolerability
Heavy (+17.3)
Subcutaneous injection
Route
Subcutaneous injection
None
Food / water rule
None
Refrigerated
Storage
Refrigerated
The call: CagriSema leads on efficacy: class leading to Survodutide's lagging (17% vs 8%). CagriSema is the easier of the two to stay on (Mild vs Heavy).
Standalone, this page carries its own key: Efficacy = % body weight lost vs placebo, on the conservative estimand that counts everyone. Tolerability = AE-discontinuation over placebo (Mild 1 to 5 · Notable 5 to 10 · Heavy over 10 points). Winners are called only across a tier or band boundary; within one, the drugs are effectively tied. The side marked leads or gentler wins that axis.
CagriSema verdict · Survodutide verdict · How this is scored